ECP-103

N/A

Report date: 2025/01/26 18:59:42
NME

Base Information

Drug NameECP-103
Drug Alias NameMYCN gene inhibitor (Nanogenics)MYCN siRNA therapy (Nanogenics)ECP-103
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionN-myc proto-oncogene protein inhibitors
TargetsN-myc proto-oncogene protein
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyboquin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRyboquin Co Ltd
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A